The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

Oncotarget

Volumn 7, Issue 3, 2016, Pages 2329-2342

  Walton, Mike I ^a   Eve, Paul D ^a   Hayes, Angela ^a   Henley, Alan T ^a   Valenti, Melanie R ^a   De Haven Brandon, Alexis K ^a   Box, Gary ^a   Boxall, Kathy J ^a   Tall, Matthew ^a   Swales, Karen ^a   Matthews, Thomas P ^a   McHardy, Tatiana ^a   Lainchbury, Michael ^a   Osborne, James ^a   Hunter, Jill E ^b   Perkins, Neil D ^b   Aherne, G Wynne ^a   Reader, John C ^c   Raynaud, Florence I ^a   Eccles, Suzanne A ^a   Collins, Ian ^a   Garrett, Michelle D ^a,d   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Sareum Ltd   (United Kingdom)

^d UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Antitumor activity; Biomarker assay; CCT245737; CHK1; Pharmacology

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CCT 245737; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; ETOPOSIDE; FIRTECAN; GEMCITABINE; IRINOTECAN; TUMOR MARKER; UNCLASSIFIED DRUG; CAMPTOTHECIN; CCT245737; CDK1 PROTEIN, HUMAN; CHEK2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; DEOXYCYTIDINE; FAMPRIDINE; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN P21; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; AUTOPHOSPHORYLATION; B CELL LYMPHOMA; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; QUANTITATIVE ANALYSIS; TUMOR CELL LINE; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINT; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; GENETICS; HT-29 CELL LINE; LUNG NEOPLASMS; LYMPHOMA, B-CELL; METABOLISM; NUDE MOUSE; TRANSGENIC MOUSE;

4-AMINOPYRIDINE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN-DEPENDENT KINASES; DEOXYCYTIDINE; DNA DAMAGE; DRUG SYNERGISM; HT29 CELLS; HUMANS; LUNG NEOPLASMS; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); PYRAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962217046     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4919     Document Type: Article

References (50)

1. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179-204.
2. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071-8.
3. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol. 2009;21:245-55.
4. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009;137:413-31.
5. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med. 2011;17:88-96.
6. McNeely S, Beckmann R, Bence Lin AK. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther. 2014;142:1-10.
7. Garrett MD, Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci. 2011;32:308-16.
8. Thompson R, Eastman A. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design. Br J Clin Pharmacol. 2013;76:358-69.
9. Lainchbury M, Collins I. Checkpoint kinase inhibitors. A patent review (2009-2010). Exp Opin Ther Patents. 2011;21:1191-210.
10. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res. 2010;16:376-83.
11. Zhang Y, Hunter T. Roles of Chk1 in cell biology and cancer therapy. Int J Cancer. 2014;134:1013-23.
12. Cho SH, Toouli CD, Fujii GH, Crain C, Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle. 2005;4:131-9.
13. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol. 2005;7:195-201.
14. Calvo E, Chen VJ, Marshall M, Ohnmacht U, Hynes SM, Kumm E, et al. Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs. 2014;32:955-68.
15. Seto T, Esaki T, Hirai F, Arita S, Nosaki K, Makiyama A, et al. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol. 2013;72:619-27.
16. Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012;18:6723-31.
17. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proceedings of the National Academy of Sciences. 2011;108:3336-41.
18. Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene. 2012;31:1661-72.
19. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11:220-8.
20. Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014;16:2-9.
21. Brooks K, Oakes V, Edwards B, Ranall M, Leo P, Pavey S, et al. A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress. Oncogene. 2013;32:788-96.
22. Cavelier C, Didier C, Prade N, Mansat-De Mas V, Manenti S, Recher C, et al. Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy. Cancer Research. 2009;69:8652-61.
23. Matthews TP, Jones AM, Collins I. Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies. Expert Opin Drug Discov. 2013;8:621-40.
24. Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, et al. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res. 2012;18:5650-61.
25. Xiao Y, Ramiscal J, Kowanetz K, Delnagro C, Malek S, Evangelista M, et al. Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor. Mol Cancer Ther. 2013;12:2285-95.
26. Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res. 2007;96:213-68.
27. Workman P. How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des. 2003;9:891-902.
28. Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, et al. The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106. Molecular Cancer Therapeutics. 2010;9:89-100.
29. Anderson VE, Walton MI, Eve PD, Boxall KJ, Antoni L, Caldwell JJ, et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 2011;71:463-72.
30. Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011;10:591-602.
31. Oza V, Ashwell S, Almeida L, Brassil P, Breed J, Deng C, et al. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas. J Med Chem. 2012;55:5130-42.
32. Davies KD, Humphries MJ, Sullivan FX, von Carlowitz I, Le Huerou Y, Mohr PJ, et al. Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo. Oncol Res. 2011;19:349-63.
33. Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther. 2008;7:2394-404.
34. King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014;32:213-26.
35. Montano R, Chung I, Garner KM, Parry D, Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther. 2012;11:427-38.
36. Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M, et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 2011;145:435-46.
37. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17 Suppl 5:7-12.
38. Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res. 2011;17:3706-15.
39. Clarke CA, Clarke PR. DNA-dependent phosphorylation of Chk1 and Claspin in a human cell-free system. Biochem J. 2005;388:705-12.
40. Sorensen CS, Syljuasen RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 2012;40:477-86.
41. Rawlinson R, Massey AJ. gammaH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments. BMC Cancer. 2014;14:483-95.
42. Del Nagro CJ, Choi J, Xiao Y, Rangell L, Mohan S, Pandita A, et al. Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death. Cell Cycle. 2014;13:303-14.
43. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt's lymphoma. Lancet. 2012;379:1234-44.
44. Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Hematology Am Soc Hematol Educ Program. 2013;2013:575-83.
45. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montana MF, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol. 2011;18:1331-5.
46. Carden CP, Sarker D, Postel-Vinay S, Yap TA, Attard G, Banerji U, et al. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov Today. 2010;15:88-97.
47. Collins I, Matthews TP, Faria da Fonseca McHardy T, Osborne J, Lainchbury M, Walton MI, et al. 5-[[4-[[Morpholin-2-yl]methylamino]-5-(trifluoromethyl-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof. Intl Patent Appl. 2013;WO2013/171470A1.
48. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The Eμ-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167:353-71.
49. Hunter JE, Butterworth J, Perkins ND, Bateson M, Richardson CA. Using body temperature, food and water consumption as biomarkers of disease progression in mice with Eμ-myc lymphoma. Br J Cancer. 2014;110:928-34.
50. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555-77.